文献速递浆细胞疾病

浆细胞疾病患者第三剂及后续新冠疫苗剂次的免疫原性与安全性

Immunogenicity and safety of a third and subsequent COVID-19 vaccine doses in patients with plasma cell dyscrasias.
PubMed 文献 · Blood Adv · 2026-01-01

这项在加拿大12个中心开展的前瞻性队列研究于2021年8月至2023年1月评估血液恶性肿瘤患者接种新冠疫苗后的体液免疫,共纳入262名参与者、983份样本,其中66%为浆细胞疾病。结果显示第三剂及后续剂次可安全提升抗S抗体免疫,尽管抗CD38治疗和年龄增长降低血清阳性率,追加接种仍可改善抗体应答。

要点

  • 第三剂及后续新冠疫苗可安全提升浆细胞疾病患者抗S抗体免疫。
  • 抗CD38治疗和年龄增长与血清阳性率降低相关。
  • 超过基础三剂的追加接种仍可增强抗体应答。

核心结论

  • 第三剂及后续新冠疫苗剂次可安全改善浆细胞疾病患者的体液免疫。
  • 抗CD38治疗和年龄增长降低血清阳性率,但追加疫苗剂次仍可增强抗S抗体应答。

研究设计与样本

  • 前瞻性队列研究,2021年8月至2023年1月在加拿大12个中心开展。
  • 共纳入262名独特参与者、983份样本,其中66%诊断为浆细胞疾病。
  • 通过指尖采血干血斑卡按接种间隔采集样本,用高通量酶联免疫吸附试验检测抗SARS-CoV-2蛋白抗体。
  • 采用逻辑回归分析不同疫苗剂次和临床风险因素与抗S血清阳性率的差异。

主要发现

  • 整个研究期间,浆细胞疾病参与者疫苗诱导的抗S免疫比例持续高于感染诱导的抗核衣壳免疫比例。
  • 疫苗应答在第三剂后6个月似乎减弱,第四剂后减弱程度较小,但后续剂次累积增加抗S免疫。
  • 抗CD38治疗和年龄增长与血清阳性率降低相关,但接受额外疫苗剂次显著改善抗S免疫。

临床怎么用

  • 对浆细胞疾病患者,尤其是接受抗CD38治疗或高龄者,应鼓励完成第三剂及后续新冠疫苗剂次以增强体液免疫。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Plasma cell dyscrasias (PCD) are a group of hematologic disorders associated with immune dysfunction from underlying disease and/or treatment. With the continued circulation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), optimizing and maintaining durable protection in this vulnerable population through vaccination remains important. A prospective cohort study was conducted between August 2021 and January 2023 across 12 sites in Canada to evaluate humoral immunity to COVID-19 vaccination in participants with hematologic malignancies. Participants were monitored longitudinally, and finger-prick dried blood spot cards were obtained at specific intervals based on vaccination. Serum antibodies against SARS-CoV-2 proteins after the third, fourth, and fifth dose were measured by high-throughput enzyme-linked immunosorbent assay. Differences in antispike (anti-S) seropositivity by vaccine dose number and clinical risk factors were analyzed by logistic regression. A total of 262 unique participants with 983 samples were included for analysis, among which 66% were diagnosed with PCD. Analysis of the predicted probability of immunity showed consistently higher proportions of participants with PCD with vaccine (anti-S) immunity compared with those with infection-derived (antinucleocapsid) immunity throughout the study. Although vaccine responses appeared to wane 6 months after dose 3 and, to a lesser extent, after dose 4, subsequent doses cumulatively increased anti-S immunity. Seropositivity decreased with anti-CD38 therapy and older age, although the receipt of additional vaccine doses significantly improved anti-S immunity. Overall, this study demonstrated that the third and subsequent COVID-19 vaccine doses could safely improve humoral immunity in participants with PCD. Although anti-CD38 therapy and age reduced seropositivity, antibody responses could still be enhanced with vaccine doses beyond the primary 3-dose series.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Bhella S, Agbayani G, Hueniken K, et al. Immunogenicity and safety of a third and subsequent COVID-19 vaccine doses in patients with plasma cell dyscrasias. Blood Adv. 2026. PMID: 41592280. doi:10.1182/bloodadvances.2025018117

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。